

Table S2. Treatments over the patients' disease course in the study cohort and according to the duration, but irrespective of the level of remission achieved during the follow-up. Number (%) of patients are reported

Treatments	Total study cohort 293	Unremitted disease 35	1-year remission 27	2-year remission 47	3-year remission 45	4-year remission 26	≥5-year remission 113	p
Hydroxychloroquine	266 (90.8)	30 (85.7)	25 (92.6)	42 (89.4)	39 (86.7)	25 (96.2)	105 (92.9)	n.s.
Methylprednisolone iv	169 (57.7)	25 (71.4)	20 (74.1)	32 (68.1)	21 (46.7)	19 (73.1)	52 (46.0)	0.002
Cumulative average PDN dose ≥180 mg/mo	78 (26.6)	21 (60)	16 (59)	16 (34)	10 (22.2)	4 (15.4)	11 (9.7)	0.02
Immunosuppressives	205 (69.9)	33 (94.3)	23 (85.1)	43 (91.5)	36 (80.0)	17 (65.4)	53 (46.9)	<0.001
Azathioprine	97 (33.1)	19 (54.3)	12 (44.4)	23 (48.9)	10 (22.2)	6 (23.1)	27 (23.0)	0.001
Mycophenolate	127 (43.3)	23 (65.7)	18 (66.7)	25 (53.2)	25 (55.6)	10 (38.5)	26 (23.0)	<0.001
Cyclosporin A	54 (18.4)	10 (28.6)	10 (37.0)	12 (25.5)	7 (15.6)	5 (19.2)	10 (8.8)	0.004
Cyclophosphamide	81 (27.6)	16 (45.7)	9 (33.3)	15 (31.9)	14 (31.1)	5 (19.2)	22 (19.5)	0.042
Methotrexate	47 (18.4)	10 (28.6)	10 (37.0)	10 (21.3)	7 (15.6)	2 (7.7)	8 (7.1)	0.001
Rituximab	22 (7.5)	8 (22.9)	5 (18.5)	7 (14.9)	1 (2.2)	0 (0)	1 (0.9)	<0.001
Belimumab	30 (10.2)	10 (28.6)	8 (29.6)	6 (12.8)	4 (8.9)	1 (3.8)	1 (0.9)	<0.001
Iv Ig	12 (4.1)	4 (11.4)	3 (11.1)	2 (4.3)	0 (0)	2 (7.7)	1 (0.9)	0.016

Iv: intravenous; PDN, prednisone; mo, month; Ig, immunoglobulins.

p values refer to chi-square test with 5 degrees of freedom (comparison among unremitted, one-, two-, three-, four- and five or more year remitted patients).